Clinical trials: Lung Tumors
Non-Small Cell Lung Cancer
Examination of Trends in Non-Small Cell Lung Cancer Patients' Medical Study Experiences
Medical study participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it…
- Trial name
- NCT05778045
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Lung Cancer
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET), (done before, during, and after chemotherapy) may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00227539
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
Thoracic Neoplasms
Prospective Study on Factors Predicting Chemo-Radiotherapy Induced Pulmonary and Esophageal Injury
The purpose of this study is to evaluate clinical, dosimetrical, functional, biological and genetic factors in predicting chemo-radiotherapy induced lung and esophagus injury.
- Trial name
- NCT00631839
- Testing
- Thoracic 3-D Conformal Radiotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Shanghai Cancer Hospital, China
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Chemotherapy Effect, Immunotherapy
Effect of Chemotherapy on TMB in NSCLC
Tumor mutation burden is identified as an important biomarkers for predicting PD-1/PD-L1 inhibitors in advanced Non-Small Cell Lung Cancer.
- Conditions
- Chemotherapy Effect, Immunotherapy, Tumor Mutation Burden, PD-1/L1 Inhibitor
- Trial name
- NCT03683407
- Testing
- Next-Genernation Sequence
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Baodong Qin
Lung Cancer, Solitary Pulmonary Nodule
4-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
This clinical trial studies positron emission tomography (PET) imaging utilizing 18F-(2S,4R)4-fluoroglutamine, a glutamic acid derivative, to image patients with Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules.
- Conditions
- Lung Cancer, Solitary Pulmonary Nodule, Cigarette Smoking Behavior
- Trial name
- GLN (NCT03568799)
- Testing
- 18F-(2S,4R)4-fluoroglutamine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lung Cancer
ENB-guided Ablation Therapy Combined With VATS in the Treatment of MPLC
The study is designed as a prospective trial whose purpose is to evaluate the effectiveness and safety of ENB-guided ablation therapy combined with VATS in the treatment of multiple primary lung cancers (MPLC).
- Trial name
- NCT04730453
- Testing
- ENB-guided ablation therapy combined with VATS
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes need for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00520845
- Testing
- celecoxib, Docetaxel, pemetrexed disodium
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non-Small Cell Lung Cancer
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
This is an open-label, multicenter, single-arm, expanded access study designed to provide alectinib to participants with ALK-rearranged NSCLC after disease progression on or intolerance to prior ALK tyrosine kinase inhibitor…
- Trial name
- NCT02271139
- Testing
- Alectinib
- Where
- 45 sites in United States
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer
Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy
There are two different treatment modes for NSCLC patients who failed to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) after initially responding to EGFR-TKI.
- Trial name
- NCT01746277
- Testing
- combined group, Sequenced group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Lung Cancer, Breast Cancer
Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.
- Conditions
- Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT06413212
- Testing
- Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Liu Huang
Lung Neoplasms
A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is a Phase II, multicenter, open-label study designed to evaluate the safety and efficacy of SHR-1210 with BP102 in subjects who are chemotherapy naive and have…
- Trial name
- NCT03666728
- Testing
- SHR-1210, BP102
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non Small Cell Lung Cancer
Maintenance Gemcitabine in the Chinese Advanced Lung Cancer
Lung cancer, the most common cancer worldwide, remains the leading cause of cancer death. Approximately two-thirds of all patients with newly diagnosed non-small-cell lung cancer (NSCLC) present with advanced stage that…
- Trial name
- MAGICAL (NCT01336192)
- Testing
- Gemcitabine, Best supportive care
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Tongji University
Lung Cancer
Pulmonary Artery Harmonic Ace+7 Energy Sealing in Open Lobectomy
VATS anatomical lung resection provides an effective minimally invasive treatment strategy for stage I and II lung cancer. VATS lobectomy is associated with significantly less postoperative atrial fibrillation, blood transfusion…
- Trial name
- NCT02456311
- Testing
- HARMONIC ACE+7
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2…
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer
- Trial name
- IL Believe (NCT05081609)
- Testing
- TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug
- Where
- 68 sites in United States, Australia and 8 more
- Volunteers
- 320 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
Non-small Cell Lung Cancer
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
A phase 3 study to evaluate the efficacy and safety of SY-3505 vs. crizotinib in patients with ALK-positive non-small cell lung cancer who had not received prior systemic therapy.
- Trial name
- NCT06254599
- Testing
- SY-3505 Capsules, Crizotinib Capsules
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
Lung Cancer
Evaluation of Deployment Capability and Accuracy of an Outside the Scope (OTS), Detachable Catheter System for Ablation of Peripheral Lung Lesions: An Ex-Vivo Human Lung Model Study
A novel OTS detachable probe system carried outside and along the flexible bronchoscope has been developed. Using this novel system, the operator can deploy the probe in the target bronchus and lesion and completely detach the…
- Trial name
- NCT04722432
- Testing
- Outside the Scope (OTS), Detachable Catheter System
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
This study aims to investigate the clinical value of small extracellular vesicle (sEV) miRNAs as predictive biomarkers for immunochemotherapy efficacy in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- NCT07070011
- Testing
- EC/EP + ICIs
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Chest Hospital of Shanghai Jiao Tong University
Mesothelioma, Homologous Recombination Deficiency
Olaparib in Patients With HRD Malignant Mesothelioma
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations).
- Trial name
- NCT04515836
- Testing
- Olaparib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Chicago
Advanced Malignant Mesothelioma, Recurrent Malignant Mesothelioma
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura.
- Trial name
- NCT00392444
- Testing
- sunitinib malate
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.